Foundayo and Weight Maintenance: Could Oral GLP-1 Pills Help After Initial Weight Loss?

Losing weight is hard. And keeping it off can be even harder.

Foundayo (orforglipron) is a newly FDA-approved oral GLP-1 pill. Notably, its approval covers not just losing weight, but keeping it off long term. In this article, we take a closer look at Foundayo and weight maintenance, including why weight maintenance is hard, what the trial data suggests, and how oral and lower-dose injectable options compare.

‍

Why Weight Maintenance Is Its Own Clinical Challenge

Despite popular opinion or belief, regaining weight after a diet or medication isn't necessarily a lack of willpower.

GLP-1 medications work by mimicking the hormone GLP-1. This hormone reduces appetite signals in the brain and slows how quickly food leaves your stomach, which helps you feel full longer. When you stop the medication or reduce the dose, these effects may be reduced. Meanwhile, your body may respond to weight loss by increasing hunger signals and adjusting how it uses energy, as it works to return to its previous weight.

In other words, the tools that helped you lose weight were actively supporting you. When you remove them, the underlying biology doesn't simply disappear.

In fact, this is why many obesity specialists now view obesity as a chronic condition, similar to high blood pressure, where ongoing management may be appropriate.

‍

What Is Foundayo (Orforglipron), and How Does It Work?

Foundayo contains orforglipron, a GLP-1 receptor agonist that works on the same appetite-regulating pathways as injectable options like semaglutide and tirzepatide.

The FDA approved Foundayo on April 1, 2026, for adults with obesity, or adults with overweight and at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. Importantly, the approval language includes maintaining weight reduction long term.

However, orforglipron is a smaller molecule, meaning it's a chemically synthesized compound, not a peptide (a chain of amino acids like the ones found in injectable GLP-1s). Peptides are typically broken down in the digestive tract, which is why most GLP-1s are injected. As a small molecule, orforglipron can be absorbed as a pill.

Foundayo is taken once daily at any time of day, with or without food, and without water restrictions. Meanwhile, oral semaglutide (Rybelsus® and the Wegovy® pill) must be taken on an empty stomach with limited water.

‍

What the Clinical Trials Show About Foundayo and Maintenance

Here's what the research shows when it comes to Foundayo and weight maintenance.

‍

ATTAIN-1 Results (Initial Weight Loss)

ATTAIN-1 was a 72-week, randomized, double-blind, placebo-controlled Phase 3 trial that included 3,127 adults without diabetes. Average starting weight was approximately 227 lbs.

At the highest dose (17.2 mg), researchers reported that participants who stayed on treatment lost an average of 27.3 lbs (12.4%), compared to 2.2 lbs (0.9%) with placebo. Across all participants, regardless of trial completion, average weight loss was 25 lbs (11.1%), compared with 5.3 lbs (2.1%) with placebo.

Lower doses showed 7.4% (17.2 lbs) weight loss at 5.5 mg and 8.3% (18.9 lbs) weight loss at 9 mg. However, keep in mind that these are averages from a controlled clinical setting, and individual results may vary.

‍

ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN (The Maintenance Evidence)

Two late-phase maintenance trials were presented at the 33rd European Congress on Obesity in May 2026. They were published in Nature Medicine (ATTAIN-MAINTAIN) and The Lancet (SURMOUNT-MAINTAIN).

ATTAIN-MAINTAIN followed adults who had already reached a weight plateau after prior treatment with semaglutide or tirzepatide in the SURMOUNT-5 study. Participants were then randomized to orforglipron or placebo for one year. After 52 weeks:

• Those previously treated with semaglutide who received orforglipron maintained an estimated 79.3% of their prior weight reduction, compared with 37.6% with placebo.
• Those previously treated with tirzepatide who received orforglipron maintained an estimated 74.7% of their prior weight reduction, compared with 49.2% with placebo.

In other words, participants receiving orforglipron maintained most of the weight reduction they had achieved during prior injectable treatment, on average.

SURMOUNT-MAINTAIN asked a different question: What happens when people step down their Zepbound® dose?

After 60 weeks on Zepbound® MTD, participants either stayed at MTD, reduced to Zepbound® 5 mg, or switched to placebo. Those who stayed on MTD preserved all of their prior weight loss on average. Those who stepped down to 5 mg maintained all but 5.6 kg (about 12 lbs).

It's worth noting that these are clinical trial results, not real-world data, and outcomes in everyday practice may differ. Both trials also focused on specific maintenance scenarios following prior injectable treatment.

‍

What These Numbers Mean in Practice

Taken together, these trials suggest that ongoing treatment may help maintain previously achieved weight reduction, although they evaluated different treatment strategies and should not be treated as a head-to-head comparison between Foundayo and continued injectable therapy.

SURMOUNT-MAINTAIN also points to another option: staying on the same medication at a lower dose. This is part of why some providers use lower, personalized maintenance doses (sometimes called microdosing) rather than stopping treatment entirely. Keep in mind that SURMOUNT-MAINTAIN studied brand-name Zepbound at a standard 5 mg dose. Lower, individualized doses have not been studied in large clinical trials, and any dose change should be made with a provider.

For some individuals, switching to a daily pill may feel like a reasonable and more sustainable choice. For others, a lower dose of their current injectable may make more sense. The right approach depends on your health history, goals, and how you've responded to treatment, which is why talking through your options with a licensed provider is so important.

‍

Oral GLP-1 Maintenance vs. Injectable: Key Differences to Understand

Choosing between oral GLP-1 maintenance and staying on an injectable involves a few trade-offs:

• Convenience: Foundayo is a once-daily pill with no food or water restrictions. For some people, this may be easier for long term use than weekly injections, especially when traveling or managing injection anxiety.
• Efficacy trade-off: Across separate maintenance trials, the data suggest switching from a high-dose injectable to Foundayo may result in somewhat more weight regain than staying on the injectable. These approaches were not directly compared in the same trial.
• Dose flexibility: Compounded semaglutide and tirzepatide, prescribed by a licensed provider and prepared by a state-licensed pharmacy, can be dosed to the individual, including lower maintenance doses. Compounded medications contain the same active ingredients as brand-name products but are not FDA-approved, and clinical trial results come from the brand-name drugs.
• Cost and access: Foundayo self-pay pricing starts at $149 per month, and a savings card may lower costs to $25 per month for eligible commercially insured patients. Injectable GLP-1 costs and insurance coverage vary widely.
• Not interchangeable: Foundayo should not be used alongside other GLP-1 receptor agonist medicines.

A licensed provider can help you weigh these factors against your specific health history, clinical profile, and goals.

‍

Who May Be a Candidate for Foundayo as a Maintenance Strategy?

You may want to consider talking with your provider regarding Foundayo if:

• You've completed an initial weight loss phase on an injectable GLP-1 and are curious about a less intensive maintenance option.
• Weekly injections have been logistically challenging, whether due to travel, storage, or injection discomfort, and a daily pill may fit your routine better.
• You're just starting weight management treatment and want to understand your long-term options from the outset.
• You've regained weight after stopping a GLP-1 medication and are exploring returning to treatment.

If injections have been working well for you, a lower, personalized dose of your current medication may be another maintenance option to discuss.

In every case, a licensed provider must evaluate you to determine your eligibility for Foundayo. Foundayo is not approved for use in children and should not be combined with other GLP-1 medications.

‍

Important Safety Considerations

Foundayo comes with important safety information, including:

• Boxed warning for thyroid tumors: Foundayo has a boxed warning regarding the potential risk of thyroid C-cell tumors. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents; however, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed with pharmacologically active GLP-1 receptor agonists in rodents has not been determined. Foundayo is contraindicated if you or a family member have ever had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
• Common side effects: These may include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, belching, heartburn, gas, and hair loss.
• Other considerations: Foundayo should not be used with other GLP-1 receptor agonists. It may also reduce the effectiveness of oral hormonal contraceptives; the prescribing information advises patients using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 30 days after starting Foundayo and for 30 days after each dose increase. Again, this is why talking with your provider is important.
• Not for cosmetic use: Foundayo is indicated for adults with obesity or overweight with weight-related medical problems. It is not a cosmetic weight loss treatment.

Before starting any new medication, review the full Prescribing Information and Medication Guide, and share your complete health history with a licensed provider.

‍

How Eden Supports Long-Term Weight Management

Ultimately, weight management doesn't end when you achieve your goal. Ongoing management may be important for maintaining weight reduction over time.

At Eden, we can connect you with a licensed healthcare provider who can help determine what's best for you. It starts with a quick online intake. If treatment is appropriate, your provider creates a care plan based on your individual evaluation (which may include compounded tirzepatide, compounded semaglutide, or Oral Weight Loss options) and your medication ships directly to your door.

As you move from weight loss into maintenance, you'll have ongoing check-ins, dose adjustments when clinically appropriate (including lower, personalized maintenance doses), and 24/7 provider messaging, so you're never navigating the next phase alone.